Shots:

• The P-III (KEYNOTE-A18) trial evaluates Keytruda + CRT (cisplatin and EBRT followed by brachytherapy) vs PBO for the treatment of newly diagnosed high-risk (stage IB2-IIB with lymph node +ve disease & stage III-IVA with/without lymph node +ve disease) locally advanced cervical cancer patients (n=1,060) with 1EPs as PFS and OS as well as 2EPs include CRR, ORR and safety
• The trial met its 1EP demonstrating improved OS with Keytruda at a pre-specified interim analysis with PFS already attained previously. Results will be highlighted at future medical meetings
• The safety results of Keytruda in the study were consistent with the prior trials without any new safety signals

Ref: Merck | Image: Merck

Related News:- Merck Reports US FDA’s Acceptance of sBLA for Keytruda Plus Chemotherapy with Priority Review for Endometrial Carcinoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com